All psychedelics remain Schedule I under federal law

Where Do Psychedelics Stand
in Your State?

State-by-state breakdown of therapeutic programs, decriminalization, and pending legislation across all 50 states. Click any state for the full picture.

Last updated: May 2026

Regulated Therapeutic Program
Statewide Decriminalization
Local Decriminalization Only
Active Legislation Pending
No State-Level Action
Alabama No State-Level Action
Alaska Active Legislation Pending
Arizona No State-Level Action
Arkansas No State-Level Action
California Local Decriminalization Only
Colorado Regulated Therapeutic Program
Connecticut Active Legislation Pending
Delaware No State-Level Action
Florida No State-Level Action
Georgia No State-Level Action
Hawaii No State-Level Action
Idaho No State-Level Action
Illinois Active Legislation Pending
Indiana No State-Level Action
Iowa Active Legislation Pending
Kansas No State-Level Action
Kentucky No State-Level Action
Louisiana No State-Level Action
Maine No State-Level Action
Maryland No State-Level Action
Massachusetts Active Legislation Pending
Michigan Local Decriminalization Only
Minnesota Active Legislation Pending
Mississippi No State-Level Action
Missouri Active Legislation Pending
Montana No State-Level Action
Nebraska No State-Level Action
Nevada No State-Level Action
New Hampshire No State-Level Action
New Jersey Active Legislation Pending
New Mexico Regulated Therapeutic Program
New York Active Legislation Pending
North Carolina No State-Level Action
North Dakota No State-Level Action
Ohio No State-Level Action
Oklahoma No State-Level Action
Oregon Regulated Therapeutic Program
Pennsylvania No State-Level Action
Rhode Island No State-Level Action
South Carolina No State-Level Action
South Dakota Active Legislation Pending
Tennessee No State-Level Action
Texas No State-Level Action
Utah Active Legislation Pending
Vermont Active Legislation Pending
Virginia No State-Level Action
Washington Local Decriminalization Only
Washington D.C. Local Decriminalization Only
West Virginia No State-Level Action
Wisconsin No State-Level Action
Wyoming No State-Level Action

The Federal Picture

What Schedule I Actually Means

Schedule I is the federal government's most restrictive drug category. It says a substance has "no currently accepted medical use" and "high potential for abuse." That designation is increasingly challenged by clinical evidence, but it has not changed yet.

State vs. Federal Tension

States cannot override federal law. What they can do is remove their own criminal penalties and deprioritize enforcement. The DEA could theoretically prosecute anyone in a "legal" state, but rarely does, for the same practical reasons it tolerates state cannabis programs.

FDA Breakthrough Designations

The FDA has granted Breakthrough Therapy designation to MDMA-assisted therapy for PTSD and psilocybin-assisted therapy for treatment-resistant depression. This designation means the FDA thinks preliminary evidence is promising. Phase 3 trials are ongoing. Approval, if it comes, is likely late 2026 to early 2027 for psilocybin.

Trump EO (April 18, 2026)

President Trump signed an executive order directing the FDA and DEA to fast-track psychedelic therapies. It shortens FDA review timelines, increases DEA production quotas for research, allocates $50 million to support state programs, and mandates rescheduling reviews after successful Phase 3 trials. It does NOT reschedule anything or legalize anything. Schedule I status stands.

DEA quotas just went up. In January 2026, the DEA published its annual production quotas. Psilocybin went from 30,000 grams to 50,000 grams (a 67% jump). Psilocin more than doubled. DMT and 5-MeO-DMT also increased. This supports more Phase II trials and accelerates the evidence base. It does not affect patient access outside of clinical trials.

What rescheduling would actually change. A successful Phase 3 trial and FDA approval would trigger a mandatory rescheduling review under the Trump EO. Moving from Schedule I to Schedule II or III would allow prescriptions, insurance coverage discussions, and mainstream medical use. That process still takes years even with the fast-track provisions.

Crossing state lines is still a federal crime. Even if you participate in a completely legal session in Oregon, taking any substance across state lines is federal drug trafficking. TSA screeners are federal employees. This is one of the hardest parts of the current legal patchwork to explain to people.

Tribal sovereignty is a separate track. Members of federally recognized tribes have had legal access to peyote for religious ceremonies since the 1994 American Indian Religious Freedom Act Amendment. This is federal-level protection, separate from any state law. The National Council of Native American Churches has asked states to exclude peyote from decriminalization measures due to conservation concerns: peyote takes 10+ years to mature, and the primary wild harvest habitat in the Rio Grande Valley is already under pressure.

Laws are changing fast.

We track it so you don't have to. Get the clearest coverage of psychedelic science and policy, straight to your inbox.

You're in.

Redirecting you now...

No spam. Unsubscribe anytime.